{"title":"FDA Approves Pralsetinib for Treatment of Adults With Metastatic RET Fusion-Positive NSCLC.","authors":"Kevin M Wright","doi":"10.46883/ONC.2020.3410.0406","DOIUrl":null,"url":null,"abstract":"<p><p>The US FDA granted accelerated approval to pralsetinib for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer.</p>","PeriodicalId":520728,"journal":{"name":"Oncology (Williston Park, N.Y.)","volume":" ","pages":"406-406;431"},"PeriodicalIF":0.0000,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology (Williston Park, N.Y.)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.46883/ONC.2020.3410.0406","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9
Abstract
The US FDA granted accelerated approval to pralsetinib for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
